BR112014028575A2 - fator de coagulaçao viii com imunogenicidade reduzida - Google Patents

fator de coagulaçao viii com imunogenicidade reduzida

Info

Publication number
BR112014028575A2
BR112014028575A2 BR112014028575A BR112014028575A BR112014028575A2 BR 112014028575 A2 BR112014028575 A2 BR 112014028575A2 BR 112014028575 A BR112014028575 A BR 112014028575A BR 112014028575 A BR112014028575 A BR 112014028575A BR 112014028575 A2 BR112014028575 A2 BR 112014028575A2
Authority
BR
Brazil
Prior art keywords
factor viii
coagulation factor
reduced immunogenicity
immunogenicity
reduced
Prior art date
Application number
BR112014028575A
Other languages
English (en)
Other versions
BR112014028575B1 (pt
Inventor
Saint-Remy Jean-Marie
Original Assignee
Imnate Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imnate Sarl filed Critical Imnate Sarl
Publication of BR112014028575A2 publication Critical patent/BR112014028575A2/pt
Publication of BR112014028575B1 publication Critical patent/BR112014028575B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/20—Ingredients acting on or related to the structure
    • A23V2200/218—Coagulant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0445—Proteins
    • A61M2202/0447—Glycoproteins
    • A61M2202/0452—Factor VIII

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014028575-6A 2012-05-22 2013-05-21 Moléculas de fator de coagulação viii, seu uso e método para reduzir a imunogenicidade das mesmas BR112014028575B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12168800.6 2012-05-22
EP12168800.6A EP2666782A1 (en) 2012-05-22 2012-05-22 Coagulation factor VIII with reduced immunogenicity.
PCT/EP2013/060397 WO2013174805A1 (en) 2012-05-22 2013-05-21 Coagulation factor viii with reduced immunogenicity

Publications (2)

Publication Number Publication Date
BR112014028575A2 true BR112014028575A2 (pt) 2017-08-01
BR112014028575B1 BR112014028575B1 (pt) 2022-08-30

Family

ID=48485166

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028575-6A BR112014028575B1 (pt) 2012-05-22 2013-05-21 Moléculas de fator de coagulação viii, seu uso e método para reduzir a imunogenicidade das mesmas

Country Status (12)

Country Link
US (1) US10087233B2 (pt)
EP (2) EP2666782A1 (pt)
JP (1) JP6363996B2 (pt)
AU (1) AU2013265400B2 (pt)
BR (1) BR112014028575B1 (pt)
CA (1) CA2872938C (pt)
DK (1) DK2852609T3 (pt)
ES (1) ES2751361T3 (pt)
HK (1) HK1203981A1 (pt)
IN (1) IN2014DN09216A (pt)
RU (1) RU2631801C2 (pt)
WO (1) WO2013174805A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3388447A1 (en) 2017-04-14 2018-10-17 Imnate Sarl Methods to produce peptides, polypeptides or cells for modulating immunity
EP3936867A1 (en) 2020-07-06 2022-01-12 Imnate Sarl Cd1 peptide-epitope for use in the treatment of a disease caused by an intracellular pathogen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084251B1 (en) * 1987-02-12 2006-08-01 Genentech, Inc. Methods and Deoxyribonucleic acid for the preparation of tissue factor protein
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
WO1995006737A1 (en) * 1993-09-03 1995-03-09 Kenneth Francis Prendergast Glycophorin binding protein (gbp130) fusion compositions
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
PL371278A1 (en) * 2002-04-18 2005-06-13 Merck Patent Gmbh Modified factor viii
PL1824988T3 (pl) 2004-11-12 2018-01-31 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja czynnika VIII
WO2006103298A2 (en) * 2005-04-01 2006-10-05 Novo Nordisk Health Care Ag Blood coagulation fviii analogues
US20090110861A1 (en) 2007-10-29 2009-04-30 3M Innovative Properties Company Pressure sensitive adhesive article
EP2711436A1 (en) * 2007-11-01 2014-03-26 University Of Rochester Recombinant factor VIII having increased stability
AU2009214040B2 (en) 2008-02-14 2013-08-22 Katholieke Universiteit Leuven Strategies to prevent and/or treat immune responses to soluble allofactors
EP2149603A1 (en) * 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
US8691211B2 (en) * 2009-03-10 2014-04-08 Puget Sound Blood Center Suppression of immune response to factor VIII in hemophilia A patients
CA2780761A1 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii t cell epitope variants having reduced immunogenicity
US9732118B2 (en) * 2010-11-25 2017-08-15 Imnate Sarl Modulation of antigen immunogenicity by deleting epitopes recognized by NKT cells

Also Published As

Publication number Publication date
IN2014DN09216A (pt) 2015-07-10
EP2666782A1 (en) 2013-11-27
JP6363996B2 (ja) 2018-07-25
AU2013265400A1 (en) 2014-11-13
HK1203981A1 (en) 2015-11-06
CA2872938C (en) 2020-06-16
CA2872938A1 (en) 2013-11-28
WO2013174805A1 (en) 2013-11-28
RU2014151719A (ru) 2016-07-10
RU2631801C2 (ru) 2017-09-26
US10087233B2 (en) 2018-10-02
EP2852609A1 (en) 2015-04-01
JP2015518844A (ja) 2015-07-06
DK2852609T3 (da) 2019-11-25
ES2751361T3 (es) 2020-03-31
AU2013265400B2 (en) 2017-07-27
BR112014028575B1 (pt) 2022-08-30
US20150087593A1 (en) 2015-03-26
EP2852609B1 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
DK2935299T3 (da) Glycokonjugationsfremgangsmåde
SMT201600451B (it) Rivestimenti superidrofobici durevoli
DK2591099T3 (da) Kimære koagulationsfaktorer
DK2859055T3 (da) Polymercoatings
DK2825087T3 (da) Otoscanner
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
FR2997014B1 (fr) Composition sterile dermo-injectable
DK2873977T3 (da) Dobbeltdækker-rørdispenser
DK2895101T3 (da) Forbedret kirurgisk template
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2854722T3 (da) Stomipose
DE102011075781A8 (de) Elektrochirurgisches Instrument
BR112014027026A2 (pt) aerofólio
FR2985500B1 (fr) Configuration d'helicoptere
FI20135047A (fi) Katseenohjausjärjestely
FI20126266A (fi) Pehmopaperin mittaus
FR2998638B1 (fr) Raccord
DK2825157T3 (da) Aminosyrelipider
FR2992610B1 (fr) Balai d'essuie-glace
BR302012004780S1 (pt) Lâmina
DE112012005756A5 (de) Ausrückvorrichtung
DK2831122T3 (da) Anthocyanidin-kompleks
CL2014002180A1 (es) Peptidos antomicrobianos
DE112013004839A5 (de) Antriebsstrang
DE112012006214T8 (de) Wulstringwickler

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/05/2013, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.